Immune monitoring of patients enrolled in vaccination trials has become crucial to help guide the development of immunotherapies and reveal potential relationships between the clinical and immunological response. The lack of protective signatures is partly explained by the realization that monoparametric evaluations fail to capture the phenotypic and functional heterogeneity of the immune response. Therefore, multiparametric flow cytometry has become the tool of choice given its ability to simultaneously analyze the relative distribution of cellular phenotypes and functions in complex mixtures of cells such as in peripheral blood and tissues.
In the case-reports presented, we will describe the tools used to comprehensively monitor antigen-specific T cells and evaluate the immunostimulatory and suppressive compartments. The analytical tools evaluate how these cellular subsets shift in phenotype and function during disease and following vaccination with the objective of discovering correlates and predictive biomarkers of immune protection.
Yoav Peretz, Ph.D., Senior Principal Scientist, Caprion/IMMUNECARTA Services
Prior to joining Caprion, Yoav Peretz held the position of Principal Scientist at the National Immune Monitoring Laboratory (NIML) where he developed customized immune monitoring assays and managed clinical and pre-clinical projects in infectious diseases and oncology. Yoav is currently Senior Scientist with Caprion/ImmuneCarta: a contract research company specialized in providing immune monitoring services to the Pharmaceutical and biotechnology industry.
Yoav Peretz earned his Masters degree in the department of Pathology at McGill University. His research focused on the intramuscular administration of hematopoietic growth factors and immune modulating molecules. He next completed his Doctoral degree in the department of Experimental Medicine where his research focused on identifying immunological signatures of protection in cohorts of HIV-infected patients. He completed his Post-Doctoral Fellowship at University of Montreal where he worked on Immune checkpoint regulators of T cell activation and studied the interaction between chronic inflammation and oxidative stress.
Who Should Attend?
Pharmaceutical and Biotechnology industries, government interested in biomarker discovery, Academia, verification, validation. Oncology, CNS, respiratory, infectious disease, toxicology, translational medicine, clinical assay development, Immune monitoring.
Caprion is a world leading provider of proteomics-based biomarker services and immune monitoring solutions to the Pharmaceutical and biotech industries.
Caprion has recently acquired the assets of the National Immune Monitoring Laboratory (NIML) and now provides immune monitoring capabilities under the IMMUNECARTA brand. Services include analysis of phenotypic and functional profiles of innate and adaptive immune responses in a GLP/GCLP compliant environment.
Caprion’s proprietary proteomics technology, CELLCARTA ®, is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of protein expression differences across large sets of biological samples.
With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has over a decade of experience providing large scale proteomics biomarker and drug target discovery and validation services for over 50 major clients in the Pharmaceutical, biotech and public sectors. Caprion also conducts internal programs aimed at discovering and developing novel in-vitro diagnostic markers for a variety of indications, including metabolic, infectious diseases and oncology, while serving as a biomarker center of excellence for the U.S. Government/NIH-NIAID for Biodefense research. Caprion Proteomics is a privately-held company owned by Chicago Growth Partners.
For more information, please visit www.caprion.com